Patents by Inventor Zhipei Wu

Zhipei Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BATTERY ASSEMBLY, BATTERY PACK, AND VEHICLE
    Publication number: 20240128535
    Abstract: A battery assembly, a battery pack and a vehicle are provided. The battery assembly includes: multiple cells; a connecting member, where the cells is electrically connected to each other through the connecting member; and a thermally conductive member, where the cell has a housing, the thermally conductive member is provided between the connecting member and the housing, and the thermally conductive member is thermally conductively connected to the connecting member and the housing.
    Type: Application
    Filed: December 7, 2023
    Publication date: April 18, 2024
    Inventors: Yuanmao SHU, Yanfeng WU, Weixin ZHENG, Zhipei LU, Huajun SUN
  • 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors
    Patent number: 10253041
    Abstract: Phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds of Formula I, formulations containing those compounds, and their use as mutant isocitrate dehydrogenase 1 enzyme inhibitors.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: April 9, 2019
    Assignee: Eli Lilly and Company
    Inventors: Renato A. Bauer, Serge Louis Boulet, Timothy Paul Burkholder, Santiago Carballares Martin, James Ronald Gillig, Raymond Gilmour, Wenceslao Lumeras, Zhipei Wu
  • 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIR USE AS MUTANT IDH1 INHIBITORS
    Publication number: 20180118759
    Abstract: Phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds of Formula I, formulations containing those compounds, and their use as mutant isocitrate dehydrogenase 1 enzyme inhibitors.
    Type: Application
    Filed: July 21, 2016
    Publication date: May 3, 2018
    Inventors: Renato A. Bauer, Serge Louis Boulet, Timothy Paul Burkholder, Santiago Carballares Martin, James Ronald Gillig, Raymond Gilmour, Wenceslao Lumeras, Zhipei WU
  • 1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors in the treatment of cancers
    Patent number: 9776992
    Abstract: 1-Oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: October 3, 2017
    Assignee: Eli Lilly and Company
    Inventors: Harold Burns Brooks, Robert Dean Dally, Timothy Barrett Durham, Kevin Robert Fales, Kwame Frimpong, Jefferson Ray McCowan, Frank George Njoroge, Timothy Alan Shepherd, Chong Si, Kenneth Jeff Thrasher, James Lee Toth, Zhipei Wu
  • 1-OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS
    Publication number: 20170233378
    Abstract: 1-Oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors.
    Type: Application
    Filed: November 24, 2015
    Publication date: August 17, 2017
    Applicant: Eli Lilly and Company
    Inventors: Harold Burns BROOKS, Robert Dean DALLY, Timothy Barrett DURHAM, Kevin Robert FALES, Kwame FRIMPONG, Jefferson Ray MCCOWAN, Frank George NJOROGE, Timothy Alan SHEPHERD, Chong SI, Kenneth Jeff THRASHER, James Lee TOTH, Zhipei WU
  • Compound useful as a c-Met inhibitor
    Patent number: 8268836
    Abstract: The present invention relates to a c-Met inhibitor or a pharmaceutically acceptable salt thereof useful in treating cancer mediated by activity of c-Met receptors.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: September 18, 2012
    Assignee: Eli Lilly and Company
    Inventor: Zhipei Wu
  • Compound Useful As A c-MET Inhibitor
    Publication number: 20120028984
    Abstract: The present invention relates to a c-Met inhibitor (disclosed herein) or a pharmaceutically acceptable salt thereof useful in treating cancer mediated by activity of c-Met receptors.
    Type: Application
    Filed: July 22, 2011
    Publication date: February 2, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventor: Zhipei Wu
  • Amidophenoxyindazoles useful as inhibitors of c-Met
    Patent number: 8030302
    Abstract: The present invention provides amidophenoxyindazole compounds useful in the treatment of cancer.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: October 4, 2011
    Assignee: Eli Lilly and Company
    Inventors: Tiechao Li, Mark Andrew Pobanz, Chuan Shih, Zhipei Wu, Wei Jennifer Yang, Boyu Zhong
  • AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET
    Publication number: 20100022529
    Abstract: The present invention provides amidophenoxyindazole compounds useful in the treatment of cancer.
    Type: Application
    Filed: July 15, 2009
    Publication date: January 28, 2010
    Inventors: Tiechao LI, Mark Andrew POBANZ, Chuan SHIH, Zhipei WU, Wei Jennifer YANG, Boyu ZHONG
  • Thiophene and furan compounds
    Patent number: 7642361
    Abstract: The present invention relates to thiophene and furan compounds and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression.
    Type: Grant
    Filed: January 5, 2005
    Date of Patent: January 5, 2010
    Assignee: Eli Lilly and Company
    Inventors: Ana Maria Castano Mansanet, Esteban Dominguez-Manzanares, Ana Maria Escribano, Maria Carmen Fernandez, William Joseph Hornback, Alma Maria Jimenez-Aguado, Eric George Tromiczak, Zhipei Wu, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Pyrrole and pyrazole derivatives as potentiators of glutamate receptors
    Patent number: 7625932
    Abstract: The present invention relates to pyrrole and pyrazole compounds of formula (I) and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression. The compounds act as potentiators on glutamate receptors, in particular AMPA and the GluR family.
    Type: Grant
    Filed: August 27, 2004
    Date of Patent: December 1, 2009
    Assignee: Eli Lilly and Company
    Inventors: Pamela Ann Albaugh, Esteban Dominguez-Manzanares, Jian Eric Hong, William Joseph Hornback, Delu Jiang, Paul Leslie Ornstein, Michelle Lee Thompson, Eric George Tromiczak, Zhipei Wu, Hamideh Zarrinmayeh, Dennis Michael Zimmerman, Ana Maria Castano Mansanet, Larry Gene Huffman, William David Miller
  • Melanocortin receptor agonists
    Patent number: 7291619
    Abstract: The present invention relates to melanocortin receptor agonists of formula (I), which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction
    Type: Grant
    Filed: January 23, 2002
    Date of Patent: November 6, 2007
    Assignee: Eli Lilly and Company
    Inventors: Christopher Kelly Biggers, Karin Briner, Christopher William Doecke, Matthew Joseph Fisher, Larry Wayne Hertel, Vincent Mancuso, Michael John Martinelli, John Philip Mayer, Paul Leslie Ornstein, Timothy Ivo Richardson, Jikesh Arvind Shah, Qing Shi, Zhipei Wu, Chaoyu Xie
  • Thiophene and furan compounds
    Publication number: 20070105852
    Abstract: The present invention relates to thiophene and furan compounds and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression.
    Type: Application
    Filed: January 5, 2005
    Publication date: May 10, 2007
    Inventors: Ana Castano Mansanet, Esteban Dominguez-Manzanares, Ana Escribano, Maria Fernandez, William Hornback, Alma Jimenez-Aguado, Eric Tromiczak, Zhipei Wu, Hamideh Zarrinmayeh, Dennis Zimmerman
  • Pyrrole and pyrazole derivatives as potentiators of glutamate receptors
    Publication number: 20070066573
    Abstract: The present invention relates to pyrrole and pyrazole compounds of formula (I) and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression. The compounds act as potentiators on glutamate receptors, in particular AMPA and the GluR family.
    Type: Application
    Filed: September 27, 2004
    Publication date: March 22, 2007
    Inventors: Pamela Albaugh, Esteban Dominguez-Manzanares, Jian Hong, William Hornback, Delu Jiang, Paul Ornstein, Michelle Thompson, Eric Tromiczak, Zhipei Wu, Hamideh Zarrinmayeh, Dennis Zimmerman, Ana Castano Mansanet, Larry Huffman, William Miller
  • Melanocortin receptor agonists
    Patent number: 7169777
    Abstract: The present invention relates to melanocortin receptor agonist of the formula I useful in the treatment of obesity, diabetes, and male and/or female sexual dysfunction
    Type: Grant
    Filed: January 23, 2002
    Date of Patent: January 30, 2007
    Assignee: Eli Lilly and Company
    Inventors: Ryan Thomas Backer, Karin Briner, Ivan Collado Caño, Oscar De Frutos Garcia, Christopher William Doecke, Matthew Joseph Fisher, Cristina Garcia-Paredes, Steven Lee Kuklish, Vincent Mancuso, Michael John Martinelli, Ana Isabel Mateo Herranz, Jeffrey Thomas Mullaney, Paul Leslie Ornstein, Zhipei Wu, Chaoyu Xie
  • Melanocortin receptor agonists
    Publication number: 20040116699
    Abstract: The present invention relates to melanocortin receptor agonist of the formula I useful in the treatment of obesity, diabetes, and male and/or female sexual dysfunction 1
    Type: Application
    Filed: July 11, 2003
    Publication date: June 17, 2004
    Inventors: Ryan Thomas Backer, Karin Briner, Ivan Collado Cano, Oscar De Frutos Garcia, Christopher William Doecke, Matthew Joseph Fisher, Cristina Garcia-Paredes, Steven Lee Kuklish, Vincent Mancuso, Michael John Martinelli, Ana Isabel Mateo Herranz, Jeffrey Thomas Mullaney, Paul Leslie Ornstein, Zhipei Wu, Chaoyu Xie
  • Melanocortin receptor agonists
    Publication number: 20040092507
    Abstract: The present invention relates to melanocortin receptor agonists of formula (I), which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction.
    Type: Application
    Filed: July 11, 2003
    Publication date: May 13, 2004
    Inventors: Christopher Kelly Biggers, Karin Briner, Christopher William Doecke, Matthew Joseph Fisher, Larry Wayne Hertel, Vincent Mancuso, Michael John Martinelli, John Philip Mayer, Paul Leslie Ornstein, Timothy Ivo Richardson, Jikesh Arvind Shah, Qing Shi, Zhipei Wu, Chaoyu Xie
  • Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
    Patent number: 6498163
    Abstract: This invention provides pyridopyrimidines and 4-aminopyrimidines that are useful for treating cell proliferative disorders, such as cancer and restenosis. We have now discovered a group of 7,8-dihydro-2-(amino and thio)pyrido[2,3-d]pyrimidines and 2,4-diaminopyrimidines that are potent inhibitors of cyclin-dependent kinases (cdks) and growth factor-mediated kinases. The compounds are readily synthesized and can be administered by a variety of routes, including orally, and have sufficient bioavailability. This invention provides compounds of Formula I: and Formula II: where W is NH, S, SO, or SO2, R1 includes phenyl and substituted phenyl, R2 includes alkyl and cycloalkyl, R3 includes alkyl and hydrogen, R8 and R9 include hydrogen and alkyl, and Z is carboxy. This invention also provides pharmaceutical formulations comprising a compound of Formula I or II together with a pharmaceutically acceptable carrier, diluent, or excipient therefor.
    Type: Grant
    Filed: August 2, 1999
    Date of Patent: December 24, 2002
    Assignee: Warner-Lambert Company
    Inventors: Diane Harris Boschelli, Annette Marian Doherty, Ali Fattaey, David William Fry, Susanne Andrea Trumpp-Kallmeyer, Zhipei Wu, Ellen Myra Dobrusin, Mark Robert Barvian
  • Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
    Patent number: 6150359
    Abstract: This invention relates to the inhibition of protein tyrosine kinase (PTK) and cell cycle kinase mediated cellular proliferation. More specifically, this invention relates to naphthyridinones and their use in inhibiting cellular proliferation and PTK or cell cycle kinase enzymatic activity.
    Type: Grant
    Filed: January 26, 2000
    Date of Patent: November 21, 2000
    Assignee: Warner-Lambert Company
    Inventors: Mark Robert Barvian, William Alexander Denny, Ellen Myra Dobrusin, James Marino Hamby, Howard Daniel Hollis Showalter, Andrew Mark Thompson, Roy Thomas Winters, Zhipei Wu
  • Amidophenoxyindazoles useful as inhibitors of c-Met
    Patent number: RE43878
    Abstract: The present invention provides amidophenoxyindazole compounds useful in the treatment of cancer.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: December 25, 2012
    Assignee: Eli Lilly and Company
    Inventors: Tiechao Li, Mark Andrew Pobanz, Chuan Shih, Zhipei Wu, Wei Jennifer Yang, Boyu Zhong